| Methods |
2‐ to 4‐week single‐blind placebo run‐in; inclusion criteria= mean sitting DBP 95‐114 mm Hg on 3 consecutive weekly visits before end of run‐in, with no more than 12 mm Hg difference in DBP between 3 visits, and difference between means at last 2 visits could not exceed 8 mm Hg; 8‐week double‐blind treatment |
| Participants |
Eprosartan 600 mg: n=123(71 males,52 females); mean age=54.0(11.1) years: baseline sitting SBP=149.3(13.3) mm Hg, DBP=100.4(4.4) mm Hg, HR=73.2(7.8) bpm;
Placebo: n=120(76 males,44 females); mean age=53.3(9.9) years; baseline sitting SBP=151.3(14.2) mm Hg, DBP=101.2(4.4) mm Hg, HR=73.1(7.7) bpm |
| Interventions |
Eprosartan 600 mg once daily;
Placebo;
taken in the morning |
| Outcomes |
Least‐squares mean change from baseline in trough sitting SBP/DBP using mercury sphygmomanometer;
Least‐squares mean change from baseline in trough standing SBP/DBP using mercury sphygmomanometer;
Least‐squares mean change from baseline in trough sitting HR;
Least‐squares mean change from baseline in trough standing HR;
WDAE |
| Notes |
BP and SE of change reported, endpoint BP and SD not reported; calculated SD of change from N and SE of change; BP data from text, p. 445 and p.446 and Figure 1, p. 447; Jadad score=3; funding source= SmithKline Beecham Pharma |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
